ライフサイエンスコーパス: brain natriuretic peptide

1 adjustment for traditional risk factors and brain natriuretic peptide.

2 several biomarkers, including N-terminal pro-brain natriuretic peptide.

3 aseline levels of hs-cTnT and N-terminal pro-brain natriuretic peptide.

4 ch immunoassay protocol for the detection of brain natriuretic peptide.

5 e prognostication in conjunction with plasma brain natriuretic peptide.

6 vated high-sensitivity C-reactive protein or brain natriuretic peptide.

7 kely to have elevated C-reactive protein and brain natriuretic peptide.

8 receptor for atrial natriuretic peptide and brain natriuretic peptide.

9 osin heavy chains, skeletal alpha-actin, and brain natriuretic peptide.

10 l class, and higher levels of N-terminal pro-brain natriuretic peptide.

11 brain natriuretic peptide or N-terminal pro-brain natriuretic peptide.

12 e, invasive hemodynamics, and N-terminal pro-brain natriuretic peptide.

13 c structure and function, and N-terminal pro brain natriuretic peptide.

14 nction, and elevated baseline N-terminal pro-brain natriuretic peptide.

15 ponin I, creatine kinase, and N-terminal pro-brain natriuretic peptide.

16 sed plasma norepinephrine and n-terminal pro-brain natriuretic peptide.

17 with lower circulating levels of atrial and brain natriuretic peptides.

18 pmol/L, P=0.041), and had a trend to higher brain natriuretic peptide (12.3 versus 7.2 pmol/L, P=0.0

19 rathyroid hormone, prolactin, N-terminal pro-brain natriuretic peptide, 25-hydroxyvitamin D) and 2 no

20 3 +/- 0.006 mug/L, P = 0.003; N-terminal pro-brain natriuretic peptide, 38.1 +/- 37.7 vs. 5.9 +/- 12.

21 nt protein 1 (117 pg/mL; 119%; P=0.004), and brain natriuretic peptide (40 pg/mL; 57%; P=0.04).

22 tors of reduced survival were elevated serum brain natriuretic peptide (482 +/- 337 pg/mL) and uric a

23 Induction of both brain natriuretic peptide (5.8-fold versus control, P:<0

24 ansformed BNP and LV-GLS were 4.04 (absolute brain natriuretic peptide: 60 pg/dL) and -20.7%.

25 racoronary group, P=0.03) and N-terminal pro-brain natriuretic peptide (-628 +/- 211 versus -315 +/-

26 131 m; P = 0.001), and serum N-terminal pro-brain natriuretic peptide (647 +/- 1,127 pg/ml vs. 1,578

27 (mean, 66 years), gender (74% male), plasma brain natriuretic peptide (79 pg/mL), left ventricular e

28 iblings, had higher levels of N-terminal pro-brain natriuretic peptide (81.7 and 69.0 pg/mL, respecti

29 Cardiac hormones atrial and brain natriuretic peptides activate guanylyl cyclase/nat

30 l prognostic information to that provided by brain natriuretic peptide alone.

31 of patients misclassified by N-terminal pro-brain natriuretic peptide and 59% (95% confidence interv

32 Patients with high brain natriuretic peptide and aminoterminal propeptide o

33 PET coupled with biologic biomarkers such as brain natriuretic peptide and antineutrophilic cytoplasm

34 Brain natriuretic peptide and atrial natriuretic peptide

35 ained even in the presence of N-terminal pro-brain natriuretic peptide and high-sensitivity troponin

36 was robustly associated with N-terminal pro-brain natriuretic peptide and incident HF or death.

37 parallel with improvement in N-terminal pro-brain natriuretic peptide and left atrial size suggest t

38 =1) at 1 month is predictive, in addition to brain natriuretic peptide and LV ejection fraction, of d

39 fraction who underwent mitral valve surgery, brain natriuretic peptide and LV-GLS provided synergisti

40 tively with pulmonary hemodynamics and serum brain natriuretic peptide and negatively with 6-minute w

41 ly specific, PlGF, as well as N-terminal pro-brain natriuretic peptide and soluble vascular cell adhe

42 atrial size) with concomitant N-terminal pro-brain natriuretic peptide and subsequent HF hospitalizat

43 as significant-but-subclinical increases in brain natriuretic peptide and troponin I.

44 , echocardiography, assays of N-terminal pro-brain natriuretic peptide and Troponin T, and functional

45 Elevated brain natriuretic peptide and uric acid, decreased left

46 Significant falls occurred in plasma brain natriuretic peptide and urinary metadrenaline excr

47 -regulation of atrial natriuretic factor and brain natriuretic peptide and with increased expression

48 nsumption), biomarker (N-terminal prohormone brain natriuretic peptide), and left ventricular functio

49 d a reduction in atrial natriuretic peptide, brain natriuretic peptide, and alpha-skeletal actin mRNA

50 These findings were all independent of brain natriuretic peptide, and assessment of NRG-1beta a

51 ded traditional risk factors, N-terminal pro-brain natriuretic peptide, and baseline hs-cTnT level.

52 hic marker genes, atrial natriuretic factor, brain natriuretic peptide, and beta-myosin heavy chain.

53 ), 6-minute walk distance, cardiac function, brain natriuretic peptide, and Borg dyspnea index.

54 ment in ventricular function, N-terminal pro-brain natriuretic peptide, and exercise capacity compare

55 ge were measured (troponin T, N-terminal pro-brain natriuretic peptide, and heart-type fatty acid bin

56 es and ejection fraction with N-terminal pro-brain natriuretic peptide, and high-sensitive troponin w

57 rinogen, D-dimer, troponin T, N-terminal pro-brain natriuretic peptide, and high-sensitivity C-reacti

58 tus, cardiac status including measurement of brain natriuretic peptide, and leukocyte antibody testin

59 Embolism Severity Index, cardiac troponin I, brain natriuretic peptide, and lower limb ultrasound tes

60 ease, chronic kidney disease, N-terminal-pro brain natriuretic peptide, and lymphocyte GRK2 protein l

61 , previous cardiopulmonary disease, D-dimer, brain natriuretic peptide, and percentage of pulmonary v

62 aphy, echocardiography, serum N-terminal pro-brain natriuretic peptide, and pulmonary function tests

63 ler-derived E/e' at echocardiography, plasma brain natriuretic peptide, and quality-of-life scores.

64 eased expression of beta-myosin heavy chain, brain natriuretic peptide, and skeletal actin and a decr

65 functional class, serum levels of N-terminal brain natriuretic peptide, and time to clinical worsenin

66 concentrations of vasopressin, aldosterone, brain natriuretic peptide, and total renin were measured

67 Atrial and brain natriuretic peptides (ANP and BNP, respectively) a

68 of beta-myosin heavy chain (betaMHC), atrial/brain natriuretic peptides (ANP/BNP), and skeletal alpha

69 gh-sensitivity troponin I and N-terminal pro-brain natriuretic peptide are also prognostic in patient

70 Atrial and brain natriuretic peptides are cleaved into smaller biol

71 First, data on the use of brain natriuretic peptide as a screening biomarker has s

72 The use of brain natriuretic peptide as a screening tool for asympt

73 , 6-minute walk distance, and N-terminal pro-brain natriuretic peptide as secondary endpoints.

74 Brain natriuretic peptide as well as biomarkers of myoca

75 ) damage and of decongestion (N-terminal pro-brain natriuretic peptide) at day 2 and worsening heart

76 ptide levels, and cardiac mRNA expression of brain natriuretic peptide, atrial natriuretic factor, an

77 Multivariable regression revealed that brain natriuretic peptide (beta=-0.250; P<0.001) and rec

78 phy gene markers atrial natriuretic peptide, brain natriuretic peptide, beta-myosin heavy chain and m

79 N-terminal pro-brain natriuretic peptide blood levels decreased by 620

80 ort-term administration of subcutaneous (SQ) brain natriuretic peptide (BNP) administration during th

81 We sampled brain natriuretic peptide (BNP) and amino-terminal (NT)-

82 Baseline brain natriuretic peptide (BNP) and C-reactive protein (

83 sed less atrial natriuretic factor (ANF) and brain natriuretic peptide (BNP) and more glucose transpo

84 Brain natriuretic peptide (BNP) and N-terminal pro-brain

85 Brain natriuretic peptide (BNP) and N-terminal proBNP (N

86 We examined whether changes in brain natriuretic peptide (BNP) and norepinephrine (NE)

87 Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are sensitive biomarkers

88 orts have suggested the usefulness of plasma brain natriuretic peptide (BNP) as a screening test for

89 mited data on the prognostic implications of brain natriuretic peptide (BNP) assessment in patients w

90 actor of activated T cells -c3 (NFATc3), and brain natriuretic peptide (BNP) compared to controls.

91 re, assessed by history of heart failure and brain natriuretic peptide (BNP) concentration at baselin

92 mine the effects of age and gender on plasma brain natriuretic peptide (BNP) concentration in a popul

93 inal atrial natriuretic peptide (NT-ANP) and brain natriuretic peptide (BNP) concentrations to show l

94 Brain natriuretic peptide (BNP) gene expression is a wel

95 hypertrophy in vivo, such as stimulation of brain natriuretic peptide (BNP) gene expression.

96 Expression of the brain natriuretic peptide (BNP) gene in cultured neonata

97 xpression profile analysis revealed that the brain natriuretic peptide (BNP) gene was significantly u

98 Brain natriuretic peptide (BNP) has an established role

99 The renal actions of brain natriuretic peptide (BNP) in congestive heart fail

100 chronic subcutaneous (SQ) administration of brain natriuretic peptide (BNP) in experimental CHF impr

101 Brain natriuretic peptide (BNP) is a cardiac peptide wit

102 Brain natriuretic peptide (BNP) is a marker of diagnosis

103 It is unknown if brain natriuretic peptide (BNP) is synthesized by CFs an

104 of LV hypertrophy (LVH) (n=121), and plasma brain natriuretic peptide (BNP) levels (n=49) were compa

105 Brain natriuretic peptide (BNP) levels are used in the e

106 ctive study to evaluate whether preoperative brain natriuretic peptide (BNP) levels predict postopera

107 We sought to determine the usefulness of brain natriuretic peptide (BNP) measurements to differen

108 We postulated that plasma brain natriuretic peptide (BNP) might serve as a biomark

109 the vascular actions of the cardiac hormone brain natriuretic peptide (BNP) on cellular proliferatio

110 a, congestion on chest radiograph, increased brain natriuretic peptide (BNP) or N-terminal prohormone

111 ongestion on chest radiograph, and increased brain natriuretic peptide (BNP) or N-terminal prohormone

112 e demonstrated strain-dependent increases in brain natriuretic peptide (BNP) secretion, BNP mRNA leve

113 Brain natriuretic peptide (BNP) serum concentration has

114 time of admission the plasma level of plasma brain natriuretic peptide (BNP) to determine its utility

115 Brain natriuretic peptide (BNP) was examined as part of

116 crosis factor-alpha receptor-1 (sTNFR-1) and brain natriuretic peptide (BNP) were highly predictive o

117 cid for atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) were increased 7- and 3-

118 the sodium calcium exchanger (Ncx1) and the brain natriuretic peptide (Bnp) whose hypertrophic upreg

119 nstant of the interaction of a 32-amino acid brain natriuretic peptide (BNP) with a mAbs and demonstr

120 agenesis to characterize the interactions of brain natriuretic peptide (BNP) with two monoclonal anti

121 tified angiotensin II as a potent inducer of brain natriuretic peptide (BNP), a hormone that recently

122 diac hormones atrial natriuretic peptide and brain natriuretic peptide (BNP), but little is known abo

123 rations of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), endothelin-1 (ET-1), re

124 rial natriuretic peptide (ANP) and B-type or brain natriuretic peptide (BNP), in the general communit

125 cluding atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), is a hallmark for malad

126 r levels of atrial natriuretic factor (ANF), brain natriuretic peptide (BNP), the RNA helicase Csm, a

127 xpression for the natriuretic peptides [ANP, brain natriuretic peptide (BNP), type-C natriuretic pept

128 te (cGMP), nitrosative/oxidative stress, and brain natriuretic peptide (BNP).

129 nction, exercise capacity, heart rhythm, and brain natriuretic peptide (BNP).

130 ctivity (44+/-15%, P<0.05) in processing pro-brain natriuretic peptide (BNP).

131 h atrial natriuretic peptide (ANP), and with brain natriuretic peptide (BNP).

132 transcription factor activates expression of brain natriuretic peptide (BNP).

133 al proatrial natriuretic peptide (N-ANP) and brain natriuretic peptide (BNP).

134 Monoclonal antibody (mAb) 106.3 binds brain natriuretic peptide (BNP)5-13(C10A) and full-lengt

135 omodulin (sTM)]) and raised plasma levels of brain natriuretic peptide (BNP, a peptide hormone associ

136 40% or less, elevated natriuretic peptides (brain natriuretic peptide [BNP] >/= 400 pg/mL or N -term

137 antagonist inhibited mechanical induction of brain natriuretic peptide but not tenascin-C.

138 the fiber direction increased expression of brain natriuretic peptide, but off-axis stretches (causi

139 Brain natriuretic peptide can be useful in distinguishin

140 and blood samples were evaluated for cardiac brain natriuretic peptide, choline, and TMAO levels.

141 Independent predictors were brain natriuretic peptide concentration > or =300 pg/ml

142 Brain natriuretic peptide concentration ranged from <4 t

143 Of those without LVSD, plasma N-terminal pro-brain natriuretic peptide concentration was greater than

144 t-for-age z score, Ross heart failure class, brain natriuretic peptide concentration, Bayley scores o

145 r volume, including central venous pressure, brain-natriuretic-peptide concentration, and fractional

146 lecules, and plasma N-terminal prohormone of brain natriuretic peptide concentrations were also measu

147 ss, Minnesota quality-of-life questionnaire, brain natriuretic peptide concentrations, and 6-minute w

148 and baseline and increases in N-terminal pro-brain natriuretic peptide concentrations.

149 anti-mitogenic activities of the atrial and brain natriuretic peptides depend upon their binding to

150 or persistently elevated amino terminal pro-brain natriuretic peptide despite treatment for heart fa

151 ependent after adjustment for N-terminal pro-brain natriuretic peptide, ejection fraction, stroke vol

152 Perfusion of isolated guinea pig hearts with brain natriuretic peptide elicited a 3-fold increase in

153 tivity cardiac troponin T and N-terminal pro-brain natriuretic peptide) emerged as the most powerful

154 vity, right ventricular function, as well as brain natriuretic peptide, endothelin-1, uric acid, and

155 Only 4 drugs (brain natriuretic peptide, exenatide, metoprolol, and es

156 dent protein kinase IIdelta phosphorylation, brain natriuretic peptide expression, and sustained capi

157 size and induction of atrial natriuretic and brain natriuretic peptide gene expression in the ventric

158 r activity and suppressed ET-induced ANP and brain natriuretic peptide gene expression.

159 chanical strain leads to activation of human brain natriuretic peptide gene promoter activity, a mark

160 es led to a dose-dependent increase in human brain natriuretic peptide gene promoter activity.

161 d selectivity of NPR-ECD (in the order ANP > brain natriuretic peptide >> C-type natriuretic peptide)

162 6 [1.02-3.39]; P=0.043) 1 month after MI and brain natriuretic peptide >100 pg/mL (2.35 [1.28-4.31];

163 re and for improved clinical outcomes with a brain natriuretic peptide-guided approach to heart failu

164 Additionally, brain natriuretic peptide has garnered significant inter

165 ntricular ejection fraction, creatinine, and brain natriuretic peptide (hazard ratio, 0.58 [95% CI, 0

166 2.133; p = 0.040), as well as N-terminal pro-brain natriuretic peptide (hazard ratio: 1.655; p < 0.00

167 pharmacological effects of infusion of human brain natriuretic peptide (hBNP) in patients with severe

168 ogical activity of orally administered human brain natriuretic peptide (hBNP).

169 ogate markers were evaluated: N-terminal-pro brain natriuretic peptide, high-sensitivity C-reactive p

170 Inclusion of N-terminal pro-brain natriuretic peptide improved the overall classific

171 However, studies of brain natriuretic peptide in patients with heart failure

172 Strong evidence exists for use of brain natriuretic peptide in the diagnosis of acute hear

173 In HF-CON, n-terminal pro-brain natriuretic peptide increased by 88 +/- 120 pg/mL

174 Importantly, proBNP (pro-brain natriuretic peptide) increased at 12 months in 20

175 nt and dysfunction and higher N-terminal pro brain natriuretic peptide independent of RA size and pre

176 Brain natriuretic peptide is the most widely studied, wi

177 Nesiritide (synthetic human brain natriuretic peptide) is approved for the treatment

178 tic peptide, and assessment of NRG-1beta and brain natriuretic peptide jointly provided better risk s

179 on problem list, inpatient loop diuretic, or brain natriuretic peptide level of 500 pg/mL or higher;

180 logy and to the subgroup with baseline serum brain natriuretic peptide levels >/=100 pg/mL.

181 [CI], -2, -16; n = 13, p = 0.015) and plasma brain natriuretic peptide levels (-19.4 fmol x ml(-1); 9

182 Secondary endpoints included brain natriuretic peptide levels and catecholamine excre

183 ment was also associated with a reduction of brain natriuretic peptide levels and no increase in the

184 igh-sensitivity troponin, and N-terminal pro-brain natriuretic peptide levels are predictive of death

185 Brain natriuretic peptide levels correlated moderately w

186 N-terminal prohormone brain natriuretic peptide levels did not increase signif

187 eased lung/body weight ratios, and increased brain natriuretic peptide levels in cMyBP-C(t3SA) mice d

188 Brain natriuretic peptide levels on admission were lower

189 At follow-up, brain natriuretic peptide levels remained stable in grou

190 Plasma brain natriuretic peptide levels rose by 56.0 and 11.5 p

191 r reductions from baseline in N-terminal pro-brain natriuretic peptide levels than did the pooled-mon

192 nd control groups; only serum creatinine and brain natriuretic peptide levels varied in laboratory ev

193 ysaccharide binding protein, troponin T, and brain natriuretic peptide levels were measured.

194 put, decreased wedge pressure, and decreased brain natriuretic peptide levels were observed in animal

195 New diagnostic tests (troponin and brain natriuretic peptide levels) are being used to aid

196 Plasma brain natriuretic peptide levels, and cardiac mRNA expre

197 um oxygen consumption, N-terminal prohormone brain natriuretic peptide levels, and left ventricular e

198 tion, plasma norepinephrine, angiotensin II, brain natriuretic peptide levels, and medications.

199 rioperative changes in left atrial pressure, brain natriuretic peptide levels, lactic acid, or renal

200 , quality of life, incidence of arrhythmias, brain natriuretic peptide levels, left ventricular eject

201 is characterized by increased N-terminal pro-brain natriuretic peptide levels, troponin release, elev

202 ricular ejection fraction, or N-terminal pro-brain natriuretic peptide levels.

203 truction, such as exercise testing and serum brain natriuretic peptide levels.

204 as assessed by measurement of N-terminal pro-brain natriuretic peptide levels; the rate of recurrent

205 of diabetes mellitus, higher N-terminal pro-brain natriuretic peptide, lower estimated glomerular fi

206 homocysteine <10 micromol/L, N-terminal pro-brain natriuretic peptide <100 pg/mL, no microalbuminuri

207 The inclusion of N-terminal pro-brain natriuretic peptide markedly improves HF risk pred

208 y echocardiography and plasma N-terminal pro-brain natriuretic peptide measurement and were followed

209 iopulmonary exercise testing, N-terminal pro-brain natriuretic peptide measurement, cardiac magnetic

210 alizations) hospitalizations in which either brain natriuretic peptide measures or ejection fraction

211 to compare urinary and plasma N-terminal pro-brain natriuretic peptide (N-BNP) in left ventricular sy

212 on) in comparison with plasma N-terminal pro-brain natriuretic peptide (N-BNP) levels.

213 Fib with activation of N-terminal atrial and brain natriuretic peptides (N-ANPs and BNPs, respectivel

214 inical heart failure trials with recombinant brain natriuretic peptide (nesiritide) failed to prove i

215 diography, an increased serum N-terminal pro-brain natriuretic peptide (NT-pro-BNP) level, and pulmon

216 he predictive capabilities of N-terminal pro-brain natriuretic peptide (NT-proBNP) and C-reactive pro

217 N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivi

218 ded whether the N-terminal of the prohormone brain natriuretic peptide (NT-proBNP) and high-sensitivi

219 The Hokusai-VTE study used N-terminal pro-brain natriuretic peptide (NT-proBNP) and right to left

220 ating plasma levels of N-terminal prohormone brain natriuretic peptide (NT-proBNP) and soluble vascul

221 Combining abnormal N-terminal pro-brain natriuretic peptide (NT-proBNP) and troponin T wit

222 Elevated levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) are associated wit

223 troponins (cTnT and cTnI) and N-terminal pro-brain natriuretic peptide (NT-proBNP) are prognostic in

224 natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) are well-establish

225 dary efficacy measure was the N-terminal pro-brain natriuretic peptide (NT-proBNP) concentration afte

226 The ventricular N-terminal pro-brain natriuretic peptide (NT-proBNP) is a marker of CHF

227 Others have reported that N-terminal pro-brain natriuretic peptide (NT-proBNP) is a valuable prog

228 ulmonary vascular resistance, N-terminal pro-brain natriuretic peptide (NT-proBNP) level, World Healt

229 n renal insufficiency and amino-terminal pro-brain natriuretic peptide (NT-proBNP) levels remains unc

230 ery in patients with elevated N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, reduces th

231 ulmonary vascular resistance, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, World Heal

232 etween renal function and amino-terminal pro-brain natriuretic peptide (NT-proBNP) levels.

233 but is associated with lower N-terminal pro-brain natriuretic peptide (NT-proBNP) levels.

234 ured troponin T and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) on postoperative d

235 Levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) provide such infor

236 The biomarker N-terminal pro-brain natriuretic peptide (NT-proBNP) was assessed.

237 N-terminal brain natriuretic peptide (NT-proBNP) was significantly

238 /ml; p < 0.001), although amino-terminal pro-brain natriuretic peptide (NT-proBNP) was superior to ST

239 biomarkers (such as N-terminal prohormone of brain natriuretic peptide (NT-proBNP)) and a measure of

240 vestigated whether plasma amino-terminal pro-brain natriuretic peptide (NT-proBNP), a marker of cardi

241 sitivity troponin T (hs-TnT), N-terminal pro-brain natriuretic peptide (NT-proBNP), and growth differ

242 cardiac troponin T (cTnT) and N-terminal pro-brain natriuretic peptide (NT-proBNP).

243 walk distance, and levels of N-terminal pro-brain natriuretic peptide (NT-proBNP).

244 O functional class, N-terminal prohormone of brain natriuretic peptide (NT-proBNP)concentrations, Bor

245 s 0.37 +/- 0.04, P = .01) and N-terminal pro-brain natriuretic peptide (NT-proBNP; 191 +/- 261 vs 33

246 T; cardiac injury biomarker), N-terminal pro-brain natriuretic peptide (NT-proBNP; cardiomyopathy bio

247 ng distance [6MWD], N-terminal prohormone of brain natriuretic peptide [NT-proBNP] concentration, and

248 (troponins I and T, N-terminal prohormone of brain natriuretic peptide [NT-proBNP]) to predict baseli

249 C-reactive protein [hs-CRP], N-terminal pro-brain natriuretic peptide [NT-proBNP], white blood cell

250 IIIB (that is stage III with N-terminal pro-brain natriuretic peptide [NTproBNP] >8500 pg/mL) diseas

251 action of nitric oxide-CAPON signalling and brain natriuretic peptide on cGMP and cAMP regulation of

252 action, and an elevated circulating level of brain natriuretic peptide or N-terminal pro-brain natriu

253 body mass index (p = 0.002), N-terminal pro-brain natriuretic peptide (p < 0.001), early mitral infl

254 P = .703), TRV (P = .503), or N-terminal pro-brain natriuretic peptide (P = .410).

255 04), and had higher levels of N-terminal pro-brain natriuretic peptide (p = 0.001) compared with less

256 erobic exercise capacity, and N-terminal pro-brain natriuretic peptide (P>0.30 for all).

257 tly correlated with N-terminal prohormone of brain natriuretic peptide (P<0.001), 6-minute walk dista

258 (IL)-6 (P=0.019), and N-terminal prohormone brain natriuretic peptide (P=0.028) concentrations were

259 nal pediatric definition; P=0.087) and lower brain natriuretic peptide (P=0.060).

260 sure and heart rate, 6-minute walk distance, brain natriuretic peptide, percent predicted carbon mono

261 patient's age, race, sex, and N-terminal pro-brain natriuretic peptide performs comparably to the ful

262 tumor necrosis factor-alpha receptor II, pro-brain natriuretic peptide (pro-BNP), and cardiac troponi

263 e LV global longitudinal strain (LV-GLS) and brain natriuretic peptide provided incremental prognosti

264 significant correlations with N-terminal pro-brain natriuretic peptide (R=0.69, P<0.001) and Troponin

265 clinically used biomarkers of heart failure: brain natriuretic peptide (r=0.691; P=0.0003), QRS (r=0.

266 hematologic response and the N-terminal pro-brain natriuretic peptide response.

267 a ratios, fetal gene expressions (atrial and brain natriuretic peptides, skeletal actin, beta-myosin

268 lified Pulmonary Embolism Severity Index and brain natriuretic peptide testing showed a negative pred

269 ood pressure and in levels of N-terminal pro-brain natriuretic peptide than the placebo group.

270 as well as a higher level of N-terminal pro-brain natriuretic peptide, than noncarriers (1194 partic

271 On addition of N-terminal pro-brain natriuretic peptide, the optimism-corrected area u

272 miR-150 outperformed N-terminal pro-brain natriuretic peptide to predict remodeling (area un

273 left atrial volume, N-terminal propeptide of brain natriuretic peptide, total, collagen-dependent, an

274 LV ejection fraction, plasma n-terminal pro-brain natriuretic peptide, tumor necrosis factor-alpha,

275 , plasma concentration of amino terminal pro-brain natriuretic peptide (univariate and multivariable

276 n, LV volumes, scar size, and N-terminal pro-brain natriuretic peptide values comparing the 2 treatme

277 eft ventricular ejection fraction, and lower brain natriuretic peptide values on admission.

278 er adjusting for serum interleukin-6 levels, brain natriuretic peptide values, and glucocorticoid use

279 25% (SD, 8) and median plasma N-terminal pro-brain natriuretic peptide was 3,070 pg/ml (interquartile

280 y decrease and no decrease in N-terminal-pro-brain natriuretic peptide was not reached and 26 months,

281 Median levels of brain natriuretic peptide were 550 pg/mL in patients wit

282 iotensin II, atrial natriuretic peptide, and brain natriuretic peptide were measured at baseline.

283 n, plasma norepinephrine, and n-terminal pro-brain natriuretic peptide were measured before (pre) and